We are live on ! Find out more
BCM

BML Capital Management Portfolio holdings

AUM $176M
1-Year Est. Return 123.21%
This Fund
S&P 500
This Quarter Est. Return
-9.94%
1 Year Est. Return
+123.21%
3 Year Est. Return
+348.91%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$140M
AUM Growth
-$11.5M
Cap. Flow
+$4.33M
Cap. Flow %
3.09%
Top 10 Hldgs %
83.64%
Holding
35
New
3
Increased
10
Reduced
4
Closed
7

Top Buys

Rank Stock Value
1
ADVM
Adverum Biotechnologies
ADVM
+$10.5M
2
ACRS icon
Aclaris Therapeutics
ACRS
+$4.22M
3
AVIR icon
Atea Pharmaceuticals
AVIR
+$3.13M
4
TECX
Tectonic Therapeutic
TECX
+$2.12M
5
VNDA icon
Vanda Pharmaceuticals
VNDA
+$2.06M

Top Sells

Rank Stock Value
1
CYT
Cyteir Therapeutics, Inc. Common Stock
CYT
+$11M
2
CLYM
Climb Bio
CLYM
+$6.01M
3
DSGN icon
Design Therapeutics
DSGN
+$1.78M
4
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
+$1.33M
5
ORKA
Oruka Therapeutics
ORKA
+$1.24M

Sector Composition

Rank Sector Weight
1 Healthcare 63.54%
2 Miscellaneous 35.06%
3 Technology 1.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGOV icon
1
iShares 0-3 Month Treasury Bond ETF
SGOV
$105B
$27.2M 19.4%
270,000
– –
AVIR icon
2
Atea Pharmaceuticals
AVIR
$468M
$21.1M 15.06%
6,375,621
+838,911
+15% +$3.13M
BIL icon
3
State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
$46.7B
$18.4M 13.1%
200,000
– –
ACRS icon
4
Aclaris Therapeutics
ACRS
$908M
$14.3M 10.2%
12,988,134
+3,592,200
+38% +$4.22M
ADVM
5
DELISTED
Adverum Biotechnologies
ADVM
$13.5M 9.62%
1,966,000
+1,132,883
+136% +$10.5M
TECX
6
Tectonic Therapeutic
TECX
$601M
$7.68M 5.48%
466,047
+132,578
+40% +$2.12M
OKUR
7
OnKure Therapeutics
OKUR
$145M
$4.04M 2.88%
267,219
+49,428
+23% +$838K
TIL icon
8
Instil Bio
TIL
$51.4M
$4.02M 2.87%
391,103
+42,368
+12% +$458K
WING icon
9
PUT
Wingstop
WING
$2.98B
$3.58M 2.56%
714
-86
-11% -$33K
ORMP icon
10
Oramed Pharmaceuticals
ORMP
$208M
$3.47M 2.47%
1,349,038
+504,542
+60% +$1.2M
CNTB
11
Connect Biopharma Holdings
CNTB
$116M
$3.11M 2.22%
2,043,248
-18,090
-0.9% -$29.7K
LONA
12
LeonaBio Inc
LONA
$71.2M
$2.38M 1.7%
90,000
– –
VNDA icon
13
Vanda Pharmaceuticals
VNDA
$328M
$2.25M 1.61%
+398,280
New +$2.06M
PMVP icon
14
PMV Pharmaceuticals
PMVP
$69M
$2.12M 1.51%
1,309,397
+2,907
+0.2% +$5.24K
ASTC icon
15
Astrotech Corp
ASTC
$15.5M
$1.96M 1.4%
220,410
– –
MIST icon
16
Milestone Pharmaceuticals
MIST
$149M
$1.46M 1.04%
1,102,895
+496,750
+82% +$798K
DSGN icon
17
Design Therapeutics
DSGN
$947M
$1.41M 1.01%
421,749
-457,729
-52% -$1.78M
VRCA icon
18
Verrica Pharmaceuticals
VRCA
$91M
$1.31M 0.94%
18,000
– –
LENZ
19
LENZ Therapeutics
LENZ
$187M
$1.11M 0.79%
63,916
– –
LSTA icon
20
Lisata Therapeutics
LSTA
$14.9M
$988K 0.7%
284,669
– –
IMA
21
ImageneBio Inc
IMA
$55.1M
$965K 0.69%
+48,760
New +$861K
FBRX
22
DELISTED
Forte Biosciences
FBRX
$946K 0.68%
70,468
– –
CALC icon
23
CalciMedica
CALC
$14.8M
$635K 0.45%
32,085
– –
VTGN icon
24
VistaGen Therapeutics
VTGN
$10.8M
$522K 0.37%
150,000
– –
ACHL
25
DELISTED
Achilles Therapeutics
ACHL
$510K 0.36%
+625,174
New +$550K
1
2

Similar funds

LFA
Legend Financial Advisors Pittsburgh, Pennsylvania $176M AUM 57.06% 1-Year Est. Return
BMCM
Black Maple Capital Management Milwaukee, Wisconsin $176M AUM 9.49% 1-Year Est. Return
KRAVCF
Karnit Road Accident Victims Compensation Fund Tel-Aviv $176M AUM
CC
Caspian Capital New York $176M AUM
ADMI
Albert D. Mason Inc Boston, Massachusetts $176M AUM 40.3% 1-Year Est. Return
DF
Dedeker Financial St. Louis Park, Minnesota $176M AUM
OL
OneFund LLC Saint Petersburg, Florida $176M AUM 42.78% 1-Year Est. Return
MP
Marcho Partners London, United Kingdom $176M AUM 7.16% 1-Year Est. Return

BML Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, BML Capital Management held 35 positions worth $140M, down 7.6% from $152M the previous quarter. Its ten largest holdings account for 84% of the portfolio.

BML Capital Management deployed $4.33M of net new capital in Q2 2024, opening 3 new positions and adding to 10 existing holdings. Its largest new stake was Vanda Pharmaceuticals: 398,280 shares worth $2.25M.

By sector, the portfolio is most concentrated in Healthcare at 64% of assets, down from 67% a quarter earlier, followed by Miscellaneous and Technology.

On the sell side, the largest reduction was Design Therapeutics, an estimated $1.78M trimmed.

  • BML Capital Management's largest Q2 2024 buy was Vanda Pharmaceuticals: 398,280 shares worth $2.25M.
  • BML Capital Management added most to Adverum Biotechnologies in Q2 2024, an estimated $10.5M increase.
  • BML Capital Management's biggest Q2 2024 reduction was Design Therapeutics, cutting an estimated $1.78M.
  • BML Capital Management fully exited Cyteir Therapeutics, Inc. Common Stock in Q2 2024, selling an estimated $11M.
  • BML Capital Management's ten largest holdings make up 84% of its $140M portfolio in Q2 2024.
  • BML Capital Management opened 3 new positions and closed 7 in Q2 2024.
  • BML Capital Management's portfolio value fell 7.6% quarter-over-quarter to $140M.

Based on BML Capital Management's 13F filing for Q2 2024, filed 7 Aug 2024.